The global pyrimethamine market size was valued at USD 1,000 million in 2021 and is projected to reach around USD 1,650 million in 2030 exhibiting a CAGR of 5.0% in the forecasted period.

The rise in the number of HIV patients across the globe, increasing prevalence of toxoplasmosis infection, growing prevalence of malaria, and surging cancer cases and chemotherapy procedures are anticipated to upsurge the market growth. However, side effects related with pyrimethamine, high cost of pyrimethamine are the factors hindering the growth of the market in the forecasted period.

Toxoplasmosis is an infection produced by a single-celled parasite called Toxoplasma gondii. The increasing prevalence of toxoplasmosis infection is projected to drive the growth of the global pyrimethamine market. According to the sources of the Centers for Disease Control and Prevention (CDC) 2018, in the U.S., a projected 11% of the 6-year-old population was diseased with Toxoplasma gondii. In various places around the world, it is projected that above 60% of people have been affected with Toxoplasma gondii. The infection rate is usually higher in areas with great humidity, heat, and lower altitudes, as oocysts endure better in these types of environments.

Promising side effects related with pyrimethamine contain occasional and probably severe hypersensitivity reactions such as toxic epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, and homophenylalanine amines, which are projected to hamper the market growth. Also, the high cost of pyrimethamine is estimated to confine the global pyrimethamine market growth over the forecasted period. For instance, the cost of Daraprim (pyrimethamine) is very high. In 2018, the list price for a one-month stock (60 tablets) in the U.S. was around US$ 45,000.

Since the COVID-19 outbreak in December 2019, the disease has extended to more than 100 nations across the world. The coronavirus (COVID 19) pandemic and following lockdown in several nations across the globe have obstructed the financial status of industries in all sectors. The coronavirus pandemic has also delayed the production, development, and supply of medicines and other healthcare products and affected the growth of the healthcare business of several companies around the world. Hence, during the forecast period, the effect of the COVID19 pandemic is also predicted to hinder the growth of the global pyrimethamine market.

Disease Type Insights
The toxoplasmosis segment led the market for pyrimethamine and accounted for the largest revenue share of around 40% in 2021. Toxoplasmosis is a contamination led by a one-celled organism known as Toxoplasma gondii. The rising frequency of toxoplasmosis inflammation is predicted to fuel the development of the global pyrimethamine market. As per the records of the CDC 2018, in the U.S., nearly 11% of the 6-year-old populace was ill with Toxoplasma gondii. In several areas over the world, it is anticipated that nearly 60% of individuals have been affected with Toxoplasma gondii. The inflammation rate is generally huge in regions with enormous heat, moisture, and less height, as saccule endure best in these forms of surroundings.

Route of Administration Insights
On the basis of route of administration, the market is segmented into oral and parenteral. In 2021, the oral segment ruled the market for pyrimethamine and held the largest market share of 79.0%. The oral segment is made up of small molecule drugs, which are considered the mainstream treatment and they are also simply managed.

Region Insights
North America is expected to dominate the global pyrimethamine market owing to an upsurge in the number of cancer cases (as pyrimethamine can persuade apoptosis of cancer cells) and chemotherapy processes in the region. For instance, as per the 2019-2021 Cancer Survival and Treatment Data and Data Report published by the American Cancer Society, as of January 1, 2019, the projected number of cancer cases in the U.S. was nearly 16,920,370.
However, Asia-Pacific has been observing a positive growth for global pyrimethamine market during the forecasted period owing to augmented government awareness programs, higher prevalence of malaria & AIDS.

Key Companies Insights
The market for pyrimethamine is moderately competitive. With the rising applications of pyrimethamine, new players are considering to enter the market. The companies are also involved in activities like joint ventures, acquisitions, partnerships, mergers, and collaborations. These activities aid in growing the effect of the players in the pyrimethamine market, ultimately boosting the market growth. 

Some of the key companies working in the global pyrimethamine market include:
• Vyera Pharmaceuticals, LLC
• Cerovene Healthcare PVT. LTD
• GlaxoSmithKline plc
• Impax Laboratories, Inc.
• NCBO BioPortal
• Pfizer, Inc.
• PRN Pharmacal
• SUDA Pharmaceuticals
• Taj Accura Pharmaceuticals
• TargetMo Chemicals Inc.
• Evaluate Ltd.
• Abcam
• Other players

Segments
By Disease Type
• Toxoplasmosis
• Malaria
• Others

By Route of Administration
• Oral
• Parenteral

By Distribution Channel
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

By Geography
• North America
o U.S.
o Canada
o Mexico
• Europe
o U.K.
o Germany
o France
o Italy
o Spain
o Russia
• Asia-Pacific
o Japan
o China
o India
o Australia
o South Korea
o ASEAN
• Latin America
o Brazil
o Argentina
o Colombia
• MEA
o South Africa
o Saudi Arabia
o UAE
o Egypt